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Abstract The P123/ACP nanocomposite with sizes less
than 100 nm consisting of triblock copolymer P123 and
amorphous calcium phosphate (ACP) has been prepared by
using an aqueous solution containing CaCl2, (NH4)3PO4,
and P123 at room temperature. The P123/ACP nanocom-
posite is used as the nanocarrier for hydrophobic drug
ibuprofen, based on the combined advantages of both
amphiphilic block copolymer and calcium phosphate
delivery system. The P123/ACP nanocomposite has a
much higher ibuprofen loading capacity (148 mg/g) than
the single-phase calcium phosphate nanostructures. The
drug release percentage of the P123/ACP nanocomposite in
simulated body ﬂuid reaches about 100% in a period of
156 h, which is much slower than that of single-phase
calcium phosphate nanostructures. It is expected that the
P123/ACP nanocomposite is promising for the application
in the controlled delivery of hydrophobic drugs.
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Introduction
Calciumphosphatesexistthroughoutthebodyintheformof
amorphous calcium phosphate as well as crystalline
hydroxyapatite [1]. They have been widely studied as ﬁllers
of bony tissues [2, 3], coatings of orthopedic implants [4],
ﬁllers of polymer bone cements [5], immovable phases for
liquid chromatography of proteins [6], and carriers of cell
cultures[7].Recently,calciumphosphateshavebeenusedto
provide transfection of DNA and deliver drugs via surface
decoration of microparticles [8–13], because calcium phos-
phates are naturally nontoxic as well as bioresorbable. Cal-
cium phosphates are native to the body, and the problems of
metabolism pathway can be greatly reduced compared to
otherdeliverysystems[14].Oneadvantageofcalciumphos-
phatesasembeddingmaterialsisthattheyarehydrophilicby
nature[15].Thus,drugswithlittlesolubilityinphysiological
liquids can be delivered through the blood stream to target
tissues using calcium phosphates if the hydrophobic drugs
can achieve an effective loading capacity.
Amphiphilic block copolymers have recently attracted
signiﬁcant attention in drug and gene delivery research
[16–18], especially for hydrophobic drugs [19]. Amphi-
philic block copolymers self-associate in aqueous solution,
forming a micellar structure with a diameter less than
100 nm. These micelles consist of a hydrophobic core
surrounded by a shell of hydrophilic blocks. The core
serves as a nonaqueous reservoir for hydrophobic drug, and
the shell interacts with the biological environment and
serves as a stabilizing interface between the hydrophobic
core and the external medium. This characteristic enables
both a high loading capacity of hydrophobic drugs and a
long circulation time resulting from the steric hindrance
due to the presence of a hydrophilic shell and the small
scale of polymeric micelles [20]. Besides, this
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cium phosphate on the hydrophilic shell.
Herein, we report the P123/ACP nanocomposite of a
typical amphiphilic triblock copolymer P123 (PEO-PPO-
PEO) and amorphous calcium phosphate (ACP) as the
nanocarrier for hydrophobic drugs, which combines the
advantages of both amphiphilic block copolymer and cal-
cium phosphate delivery system. The structure of P123
block copolymer micelles consists of hydrophilic PEO
chains attached to the surface of the hydrophobic PPO
cores. And the amorphous calcium phosphate is coated on
the micelles. A typical hydrophobic drug, ibuprofen, is
used to investigate the drug loading and in vitro release
behavior in simulated body ﬂuid (SBF). The P123/ACP
nanocomposite has higher ibuprofen loading capacity and
superior sustained-release property compared with single-
phase calcium phosphate delivery system, thus it is
promising for the application in hydrophobic drug delivery.
Materials and Methods
Preparation of the P123/ACP Nanocomposite
The P123/ACP nanocomposite was prepared as follows:
The reaction temperature was kept at room temperature.
0.100 g P123 was dissolved in 40 mL deionized water
under magnetic stirring. An amount of 1.5 mL 0.5 M
CaCl2 aqueous solution was added to the above solution
under magnetic stirring. Then, 0.9 mL of 0.5 M (NH4)3PO4
aqueous solution was added and magnetically stirred for
30 min. The product was collected by centrifugation and
washed by centrifugation-redispersion cycles with deion-
ized water and alcohol three times, respectively.
Preparation of Single-Phase Calcium Phosphate
Nanostructures
The single-phase calcium phosphate nanostructures were
prepared as follows: The reaction temperature was kept at
37C. The pH value of the reaction system was kept at 10.
Solution A was prepared by dissolving 1.387 g CaCl2 in
75 mL deionized water. Solution B was prepared by dis-
solving 0.990 g (NH4)2HPO4 in 25 mL deionized water.
Then, solution B was added to solution A. The product was
collected by centrifugation and washed by centrifugation-
redispersion cycles with deionized water and alcohol three
times, respectively.
Characterization of Samples
The as-prepared samples were characterized using X-ray
powder diffraction (XRD) (Rigaku D/max 2550 V, Cu Ka
radiation, k = 1.54178 A ˚), transmission electron micros-
copy (TEM) (JEOL JEM-2100F), selected-area electron
diffraction (SAED), and energy dispersive spectroscopy
(EDS). The Fourier transform infrared (FTIR) spectra were
taken on a Nexus FTIR spectrometer (Thermo Nicolet,
USA). The Brunauer–Emmett–Teller (BET) surface area
was measured with an accelerated surface area and po-
rosimetry system (ASAP 2010, USA). The ibuprofen
concentrations were analyzed using a UV–Vis spectro-
photometer (UV-2300, Techcomp) at a wavelength of
263 nm.
Drug Loading and In Vitro Drug Release
The typical drug loading and in vitro drug release experi-
ments were performed as follows: 1 g of P123/ACP
nanocomposite or single-phase calcium phosphate nano-
structures was added into 40 mg mL
-1 ibuprofen hexane
solution. The suspension was shaken in a sealed vessel at
37C for 24 h during which the evaporation of hexane was
prevented. The sample with loaded drug was separated
from the solution, dried, and compacted into disks (each
disk 0.3 g) by a pressure of 4 MPa. Each disk was
immersed into 200 mL of simulated body ﬂuid (SBF) with
pH 7.4 at 37C with a constant shaking. The shaking device
was a desk-type constant-temperature oscillator (THI-92A,
China). The release medium (2 mL) was taken out for
analysis by UV–Vis absorption spectroscopy at a wave-
length of 263 nm at given time intervals and replaced with
the same volume of fresh preheated SBF (37C).
Results and Discussion
Figure 1a shows the TEM micrograph of the P123/ACP
nanocomposite prepared by using an aqueous solution
containing CaCl2, (NH4)3PO4, and P123, which reveals the
porous nanostructures with diameters less than 100 nm.
EDS analysis (Fig. 1b) shows that the P123/ACP nano-
composite consists of calcium and phosphorus, and the Cu
peak is originated from the copper sample holder. SAED as
well as XRD pattern indicates that the P123/ACP nano-
composite is amorphous. The BET speciﬁc surface area
reaches 79.3 m
2/g. As a reference, single-phase calcium
phosphate nanostructures were also prepared without using
P123, which exhibit a bundle-like morphology consisting
of nanorods, as shown in Fig. 1c. And SAED and XRD
data indicate that the single-phase calcium phosphate
nanostructures are also amorphous.
Figure 2 shows the FTIR spectrum of the P123/ACP
nanocomposite. The broad strong peak at around
3,427 cm
-1 is assigned to the adsorbed water. The char-
acteristic bands of CH3,C H 2, and CH in P123 are located
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-1. The band at 1,637 cm
-1
is assigned to the bending mode of the OH
- vibration. The
intense peaks located at 1,051 and 567 cm
-1 are assigned
to PO4
3-. The characteristic band in the range of 1,100 and
1,000 cm
-1 is due to the C–O stretching vibration, which is
also a feature of P123; however, it is overlapped with the
peak of PO4
3-.
It has been reported that P123 self-assembles in water
into spherical micelles at ambient temperatures [21]. A
P123 micelle consists of a hydrophobic core (PPO block)
with a radius of 4.8 nm and a hydrophilic corona (PEO
block) with a thickness of 4.6 nm, so that the diameter is
around 18 nm [22]. And generally spherical micelles
aggregate together [23, 24]. These are consistent with the
as-prepared P123/ACP nanocomposite. It is obvious that in
the present reaction system, the amorphous calcium phos-
phate formed in a hydrophilic environment, thus leading to
its coating on the hydrophilic corona (PEO block). As
displayed in Fig. 1a, the as-prepared samples are composed
of aggregated particles. Combining the results obtained
from Figs. 1b and 2, one can see that these aggregated
particles consist of calcium phosphate and P123. In short, it
can be concluded that the P123/ACP nanocomposite
formed as following: ﬁrst, P123 self-assembled into
spherical micelles and aggregated together; then amor-
phous calcium phosphate generated out of the hydrophilic
PEO block when Ca
2? and PO4
3- were added into the
aqueous solution and coated on the micelles.
We explored the possibility of using the P123/ACP
nanocomposite as the nanocarrier for drug loading and
prolonged drug release. The UV–Vis absorption spectra of
the hexane solution containing ibuprofen before and after
ibuprofen loading in samples are shown in Fig. 3a–c (each
solution was diluted 50 times). One can see that the
absorption spectra of ibuprofen in hexane solution show the
characteristic absorption peaks of ibuprofen. On the basis
of the calculation from the standard concentration cali-
bration curve dependent on the absorbance of ibuprofen at
263 nm, the ibuprofen storage in the P123/ACP nano-
composite is 148 mg/g, obviously higher than the value of
the single-phase calcium phosphate nanostructures
(118 mg/g), indicating the signiﬁcant synergic effect of
P123 and calcium phosphate on the drug loading.
Figure 4 shows the drug release behaviors of the samples
in simulated body ﬂuid. The ibuprofen–P123/ACP nano-
composite system exhibits a much lower release rate and
sustained release of ibuprofen (Fig. 4a), which can prevent
the explosive release of ibuprofen and prolong the drug
effect. One can see that about 27% of the loaded drug is
releasedin the ﬁrst 12 h, then the drug releaserate decreases
and maintains relatively constant, and reaches a value 49%
in 48 h and 100% in 156 h. In contrast, the drug release rate
of the ibuprofen–single-phase calcium phosphate system
Fig. 1 TEM micrograph: (a)
and EDS spectrum (b) of the
P123/ACP nanocomposite.
(c) TEM micrograph of the
single-phase calcium phosphate
nanostructures with a nanorod
morphology
Fig. 2 FTIR spectrum of the P123/ACP nanocomposite
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123(Fig. 4b) is much faster, and more than 90% of the loaded
drug is released in 48 h. This experimental result strongly
reﬂects the signiﬁcant synergic effect of P123 and calcium
phosphate on the drug release behavior, due to the effect of
hydrogen bonds between –OH group of P123 and –COOH
group of ibuprofen molecules.
Calcium phosphates, regardless of Ca:P ratio, crystal-
linity, or crystal phase, are relatively insoluble at physio-
logical pH but have increasing solubility in the acidic
environments[1,15].ThispH-dependentsolubilityprovides
an advantage in the controlled drug delivery. AndP123 isan
importanttemperatureresponsivetriblockcopolymer.Thus,
the P123/ACP nanocomposite may also be developed as
both pH- and temperature-responsive drug delivery system.
Future work will focus on the pH- and temperature-
responsive property of these P123/ACP nanocomposites.
Conclusions
In summary, we have prepared the P123/ACP nanocom-
posite with sizes less than 100 nm by using an aqueous
solution containing CaCl2, (NH4)3PO4, and P123 at room
temperature. The P123/ACP nanocomposite has been
explored as the nanocarrier for hydrophobic drug ibuprofen
on the basis of the advantages of both amphiphilic block
copolymer and calcium phosphate delivery system. The
P123/ACP nanocomposite has a much higher ibuprofen
loading capacity (148 mg/g) than the single-phase calcium
phosphate nanostructures and has a prolonged drug release
behavior in simulated body ﬂuid (156 h), which is much
slower than that of single-phase calcium phosphate nano-
structures. It is expected that the P123/ACP nanocomposite
is promising for the application in the controlled delivery
of hydrophobic drugs.
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